Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
Harbour BioMed announced a global out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody (HBM7022), a novel bispecific antibody generated from HBM’s HCAb Based Immune Cell Engagers (HBICE®) Platform.
Harbour BioMed out-liscense agreement with AstraZeneca marks a major milestone in Harbour BioMed business development with the agreement and recognition by an industry-leading global biopharmaceutical company and validating the potential of the company’s technology platform and innovation capabilities.
HBM7022 is a pre-clinical stage, bispecific antibody, that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and CD3, and thus leads to potent T cell activation and tumor elimination.
AstraZeneca will be granted an exclusive global license for research, development, registration, manufacturing, and commercialization of HBM7022 upon the execution of the license agreement.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said, “HBM7022, one of our representative innovative bispecific antibodies generated from the HBICE® platform, has significant potential value on a global basis. We are happy to reach this agreement with AstraZeneca, a leading innovator in oncology with a diverse portfolio and pipeline of life-changing medicines. We are very confident that AstraZeneca will maximize the value of HBM7022 to realize the potential of the molecule.
Dr. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said, “We are excited to enter into this agreement with Harbour BioMed for the development of the next-generation bispecific antibody HBM7022. This molecule is designed to harness the body’s immune system T cell response, with potential for strong efficacy across solid tumors including gastric and pancreatic cancers, both of which comprise large populations of patients with major unmet medical need.”
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.